Upregulation of PPARγ in tissue with gastric carcinoma

Hybridoma

Volumn 29, Issue 4, 2010, Pages 341-343

  Yao, Liping ^a   Liu, Fei ^a   Sun, Li ^a   Wu, Hanping ^a   Guo, Changcun ^a   Liang, Shuhui ^a   Liu, Lili ^a   Liu, Na ^a   Han, Zheyi ^a   Zhang, Hongbo ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; PEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CHRONIC GASTRITIS; FEMALE; GASTROINTESTINAL DYSPLASIA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION; UPREGULATION; CELL DIFFERENTIATION; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GASTRITIS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH MUCOSA; STOMACH TUMOR;

ADULT; AGED; CELL DIFFERENTIATION; FEMALE; GASTRIC MUCOSA; GASTRITIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PPAR GAMMA; PROGNOSIS; STOMACH NEOPLASMS; UP-REGULATION; YOUNG ADULT;

EID: 77955902983     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2010.0013     Document Type: Article

References (13)

1. Blackburn GL: From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma modulators. Am J Clin Nutr 2010;91(1):251-253.
2. Cheatham WW: Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010;91(1):262S-266S.
3. Higgins LS, and Depaoli AM: Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010;91(1):267-272.
4. Nofziger C, and Blazer-Yost BL: PPARgamma agonists, modulation of ion transporters, and fluid retention. J Am Soc Nephrol 2009;20(12):2481-2483.
5. Ehrenborg E, and Krook A: Regulation of skeletal muscle physiology and metabolism by peroxisome proliferatoractivated receptor delta. Pharmacol Rev 2009;61(3):373-393.
6. Mannucci E, and Monami M: Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? Curr Diabetes Rep 2009;9(5):342-347.
7. Broadhead ML, Dass CR, and Choong PF: Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med 2009;15(10):461-467.
8. Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Invest Drugs 2009;10(10):1085-1090.
9. Jeninga EH, Gurnell M, and Kalkhoven E: Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab 2009;20(8):380-387.
10. Kurtz TW, and Klein U: Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32(10): 826-834.
11. Pothoulakis C: Anti-inflammatory mechanisms of action of Saccharomyces boulardii [review]. Aliment Pharmacol Ther 2009;30(8):826-833.
12. Luo YQ, Wu KC, Sun AH, Pan BR, Zhang XY, and Fan DM: Significance of COX-1, COX-2, Inos expression in superficial gastritis, gastric mucosal hyperplasia and gastric carcinoma. Chin J Dig 2000;20:223-368.
13. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA: Peroxisome proliferator-activated receptor a and g are activated by indomethancin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.